Related Experiment Video

Updated: Sep 2, 2025

A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators
07:41

A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators

Published on: February 20, 2018

9.0K

Guanylyl cyclase C as a diagnostic and therapeutic target in colorectal cancer

Adi Caspi1, Ariana A Entezari1, Madison Crutcher1,2

  • 1Department of Pharmacology, Physiology, & Cancer Biology, Thomas Jefferson University, Philadelphia, PA 19107, USA.

Personalized Medicine
|August 3, 2022
PubMed

Insights

Guanylyl cyclase C (GUCY2C) is a promising tumor suppressor and biomarker for colorectal cancer. Its universal expression in advanced tumors offers new avenues for targeted gastrointestinal malignancy therapies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Gastroenterology

Background:

  • Colorectal cancer (CRC) is a leading cause of cancer mortality in the USA.
  • Current CRC treatments like surgery and chemotherapy are generalized and lack specificity.
  • Advances in personalized medicine highlight the need for novel molecular targets and biomarkers for CRC.

Purpose of the Study:

  • To identify and evaluate potential molecular targets and biomarkers for colorectal cancer.
  • To explore the role of guanylyl cyclase C (GUCY2C) as a therapeutic target and diagnostic marker in gastrointestinal malignancies.

Main Methods:

  • Literature review and analysis of existing research on colorectal cancer targets.
  • Examination of the expression patterns and functional role of GUCY2C in colorectal tumors.
  • Assessment of GUCY2C's characteristics as a potential biomarker for gastrointestinal cancers.

Main Results:

  • Guanylyl cyclase C (GUCY2C) acts as a tumor suppressor in the intestine.
  • GUCY2C is consistently expressed in advanced metastatic colorectal tumors.
  • GUCY2C is also found in other cancers originating from intestinal metaplasia.

Conclusions:

  • GUCY2C presents a compelling molecular target for colorectal cancer therapy.
  • The expression profile of GUCY2C makes it a valuable biomarker for gastrointestinal malignancies.
  • Targeting GUCY2C aligns with the goals of personalized oncology and targeted therapies.
Keywords:
GUCY2Cbiomarkercancer preventioncolorectal cancerguanylinguanylyl cyclase Chormone replacementlinaclotideplecanatideuroguanylin

More Related Videos

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

13.9K
Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer06:24

Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer

Published on: October 13, 2023

1.1K

Related Concept Videos

GPCRs Regulate Adenylyl Cylase Activity01:09

GPCRs Regulate Adenylyl Cylase Activity

Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of...
5.8K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
2.7K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.7K